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ABSTRACT
The DNA mismatch repair (MMR) system corrects DNA replication mismatches 
thereby contributing to the maintenance of genomic stability. MMR deficiency has 
been observed in prostate cancer but its impact on the genomic landscape of these 
tumours is not known. In order to identify MMR associated mutations in prostate 
cancer we have performed whole genome sequencing of the MMR deficient PC346C 
prostate cancer cell line. We detected a total of 1196 mutations in PC346C which was 
1.5-fold higher compared to a MMR proficient prostate cancer sample (G089). Of all 
different mutation classes, frameshifts in mononucleotide repeat (MNR) sequences 
were significantly enriched in the PC346C sample. As a result, a selection of genes with 
frameshift mutations in MNR was further assessed regarding its mutational status in 
a comprehensive panel of prostate, ovarian, endometrial and colorectal cancer cell 
lines. We identified PRRT2 and DAB2IP to be frequently mutated in MMR deficient cell 
lines, colorectal and endometrial cancer patient samples. Further characterization of 
PRRT2 revealed an important role of this gene in cancer biology. Both normal prostate 
cell lines and a colorectal cancer cell line showed increased proliferation, migration 
and invasion when expressing the mutated form of PRRT2 (ΔPRRT2). The wild-type 
PRRT2 (PRRT2wt) had an inhibitory effect in proliferation, consistent with the low 
expression level of PRRT2 in cancer versus normal prostate samples.
INTRODUCTION
DNA mismatch repair (MMR) is a highly conserved 
repair mechanism responsible for the correction of 
mismatched base pairs occurring during the DNA 
replication process [1]. Defects in this repair mechanism 
are associated with mutations in microsatellite repeat 
sequences [2], which consist of tandemly repeated 
motifs of one (mono) to six (hexa) nucleotides [3]. The 
mismatch repair heterodimers MSH2/MSH6 and MSH2/
MSH3 detect replication errors and recruit the MLH1/
PMS2 complex which in turn degrades and resynthesizes 
the mutated stretch [4]. When MMR is defective, these 
errors will not be corrected and will lead to frequent 
microsatellite instability (MSI) [2].
Most microsatellite sequences are located in 
non-coding DNA with limited consequences to cell 
functions [5]. But recently, defects in MMR were shown 
to originate a mutator phenotype with an increased rate 
of frameshift mutations in genes including those with 
coding microsatellites [6]. Affected genes are involved 
in signal transduction pathways (TGFβRII, IGFIIR and 
PTEN) [7–9], apoptosis (BAX and CASP5) [10, 11], 
DNA repair (MBD4) [12], and transcriptional regulation 
(TCF-4, EPHB2, AXIN2) [13–15]. The proteins resulting 
from these frameshift mutations can contribute to tumour 
progression by functional inactivation, a dominant 
negative effect, or a gain of function [16–18].
Germline mutations in MMR genes are present 
in over 90% of Lynch syndrome patients, which are 
characterized by MSI and an increased risk of colorectal 
cancer and several other cancer types [19]. The MSI 
phenotype is also observed in approximately 15% of 
sporadic colorectal cancers [20], 12% of ovarian cancers 
[21], 20% of endometrial cancers [22, 23], 30% of gastric 
cancers [24] and less frequent in other cancer types [25]. 
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MMR deficiency is also frequent in in vitro growing 
prostate cancer cell lines. LNCaP cells do not express 
MSH2 due to gene deletion and MLH1 is mutated in 
DU145, resulting in expression of an unstable truncated 
MLH1 protein [26, 27]. The frequency of MSI reported 
in prostate cancer patients varies considerably between 
different studies but it is conclusively lower than in other 
sporadic cancer types [28, 29].
So far, no whole genome sequencing study has 
focused on identifying novel genes commonly targeted 
by MMR deficiency in prostate cancer. Whole genome 
sequencing of two prostate cancer samples, one with 
a functional MMR system (G089, a late stage prostate 
cancer patient) and other with deficiency of the MMR 
system (PC346C, a prostate cancer cell line with point 
mutations in both alleles of the MSH2 gene) [30] 
identified numerous novel gene mutations. Mutations in 
mononucleotide repeats (MNR) were most specific for 
the PC346C sample. A set of 17 candidate genes with 
mutations in MNR was defined and further evaluated 
in a larger panel of prostate, colorectal, endometrial 
and ovarian cancer cell lines. We identified proline-rich 
transmembrane protein 2 (PRRT2) and DAB2 interacting 
protein (DAB2IP) to be frequently mutated in all different 
cancer cell line types. Further analysis showed that both 
genes were also frequently mutated in colorectal and 
endometrial cancer patient samples. Functional studies 
revealed PRRT2 to be implicated in cellular proliferation 
and migration with the truncated MSI-derived PRRT2 
form promoting both processes.
RESULTS
Overview of microsatellite mutations in gene 
sequences
To identify novel gene mutations caused by MMR 
deficiency in prostate cancer, we analyzed the whole 
genome sequence of the MMR-deficient prostate cancer 
cell line PC346C and the MMR-proficient prostate 
cancer patient sample (G089). We selected for mutations 
that would likely disrupt the normal protein function 
(insertion/deletion introducing frameshifts, and mutations 
in the start or stop codon). The sequence flanking each 
gene mutation (10 nucleotides up and downstream) was 
retrieved using the UCSC genome browser. We selected 
for mutations occurring in microsatellite sequences in the 
PC346C sample and absent in G089, thereby enriching for 
mutations that are caused by MMR deficiency. First, the 
type and length of repeats were used to attain an overview 
of the mutation spectrum in both prostate cancer samples 
(Figures 1A, 1B and 1C). We included in our studies 
repeats with three or more repeat units, depending on the 
repeat composition (mono-, di- or tri-nucleotide repeat). 
Overall, we detected 1196 gene mutations in PC346C and 
760 gene mutations in G089 (Supplementary Tables 1 and 
2). From the 1196 gene mutations in PC346C, 303 were 
in mononucleotide repeats (MNRs), 79 in dinucleotide 
repeats (DNRs) and 19 intrinucleotide repeats (TNRs) 
(6x n1 for MNR, 3x n2 for DNR and 3 x n3 for TNR) 
(Supplementary Figure 1A). In G089, 47 gene mutations 
were in MNRs, 56 in DNRs and 19 in TNRs (6x n1 for 
MNR, 3x n2 for DNR and 3 x n3 for TNR) (Supplementary 
Figure 1B).
PC346C had a 1.5-fold increase in the number 
of mutated genes as compared to G089. The number of 
mutations found in MNR sequences of 6 nucleotides 
was 6-fold higher in PC346C. A 6-fold increase in MNR 
gene mutations in PC346C was also observed for MNRs 
of length n8. Since MNRs showed, compared to di- and 
tri-nucleotide repeats, a higher incidence of mutations in 
MSI+ cancers we focused on these repeats.
We separated the mutated genes in PC346C and 
G089 in A, T, C and G MNRs categories of different 
lengths (Supplementary Table 3). The UCSC build hg18 
was used as reference for gene annotation. The number of 
C and G MNRs in reference genes was considerable lower 
than that of A and T repeats. As expected the mutations in 
C and G MNRs in PC346C and G089 was also much lower 
than that of A and T MNRs (Supplementary Table 3).
Novel target genes of microsatellite instability
To specifically select novel gene mutations 
associated with MMR deficiency with expected functional 
impact we first filtered for mutations in MNR sequences in 
PC346C, which were 6 nucleotides or longer. We excluded 
LOC annotated gene symbols and genes already known to 
be associated with MMR deficiency or MSI by using the 
text mining software Anni 2.0. (http://biosemantics.org/
index.php/software/anni). We identified over 35 mutated 
genes in PC346C, which were already known as targets 
of MSI or are associated with MMR deficiency including 
TGFβRII, PTEN, BAX, MLH3, MSH6 and MSH2. The 
frequent identification of known MMR-associated genes 
confirmed the validity of our approach. This procedure left 
119 genes for further selection. Next, Ingenuity Pathway 
Analysis (IPA) was used to identify genes with functions 
most likely to be cancer-associated, like cell cycle, cellular 
growth, apoptosis and other important cell signaling 
pathways. Finally, we checked the expression profile of 
candidate genes using Affymetrix exon array data of 90 
prostate cancer RNA samples and 17 normal controls 
(Supplementary Materials and Methods). A final subset of 
14 novel genes showing MNR mutations and differential 
expression between normal and prostate cancer samples 
was assessed for their mutation status in a larger panel of 
cancer cell lines (Table 1). As positive controls we added 
three known MSI target genes (PHACTR4, MLL3 and 
CEP164).
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Frequency of microsatellite instability target 
genes
Microsatellite status of the set of target genes was 
examined in three MMR-proficient prostate cancer cell 
lines and in four MMR-deficient prostate cancer cell lines 
(Figure 2, Supplementary Table 4, Supplementary Figure 
2). None of the MMR-proficient prostate cancer cell lines 
showed MSI in the selected gene panel. Controls CEP164, 
PHACTR4 and MLL3 were mutated in two or more of the 
MMR-deficient cell lines. We found that CNOT1, DAB2IP 
and PRRT2 were mutated in at least three MMR-deficient 
cell lines (Figure 2, Supplementary Table 4).
Next, we expanded the cell line panel with ten 
colorectal, four endometrial and three ovarian cancer 
MMR-deficient cell lines together with control MMR-
proficient cell lines of each cancer type. As observed in 
the MMR-proficient prostate cancer cell lines, colorectal, 
endometrial and ovarian cancer MMR-proficient cell 
lines showed no mutations in the analysed genes (Table 
2 and Supplementary Table 5). The control genes 
CEP164, PHACTR4 and MLL3 displayed as expected 
high mutation frequencies, ranging from 30% to 80% in 
the MSI cancer cell lines (Table 2 and Supplementary 
Table 5). Also here we identified CNOT1, DAB2IP and 
PRRT2 as novel MSI target genes, in the MMR-deficient 
cancer cell lines, although with varying frequency. The 
genes displayed mostly deletions and to a lesser extend 
insertions (Table 2 and Supplementary Table 5). The 
mutations shifted the open reading frame of the affected 
genes and consequently predicted to result in synthesis 
of truncated proteins due to premature termination 
(Supplementary Table 1). CNOT1 contains a n13 A 
repeat in the open reading frame located 10 nucleotides 
upstream of the stop codon. A frameshift mutation at 
this position might not be critical for the protein and no 
further research was conducted for this gene. The n9 C 
repeat in PRRT2 and the n8 C repeat in DAB2IP displayed 
a mutation pattern reflecting both insertions and deletions. 
(Supplementary Figure 3A, 3B).
Frequency of PRRT2 and DA2IP repeat 
mutations in MSI patient cancer samples
Next, we checked whether the mutation frequencies 
of PRRT2 and DAB2IP observed in the cancer cell line 
Figure 1: Overview of the mutation spectrum in G089 and PC346C genomic DNA. Genes with mutations in mononucleotide 
repeats (MNRs) A., dinucleotide repeats (DNRs) B. and trinucleotide repeats (TNRs) C. were distributed according to the length of the 
mutated repeat sequence. The repeat unit length for MNRs is one nucleotide (n=1), for DNRs it is two nucleotides (n=2) and for TNRs it 
is three nucleotides (n=3). The x-axis shows the number of repeat units: 6, 8 and 10 in case of MNRs; 3x, 4x and 5x in case of DNRs and 
TNRs.
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Table 1: List of microsatellite instability target genes in PC346C
Gene Name Length of repeat Mutation in PC346C
CNOT1 CCR4-NOT transcription complex, sub 1 A13 del AA
DAB2IP DAB2 interacting protein C8 del C
PRRT2 proline-rich transmembrane protein 2 C9 ins CC
TTC3 tetratricopeptide repeat domain 3 A8 del A
CEP164 centrosomal protein 164kDa A11 del A
PHACTR4 phosphatase and actin regulator 4 A10 del A
TROVE2 TROVE domain family, member 2 A9 del A
ZFR zinc finger RNA binding protein T9 del T
MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 T9 del T
ANLN anillin, actin binding protein A7 del A
ANUBL1 AN1, ubiquitin-like, homolog A7 del A
EPRS glutamyl-prolyl-tRNA synthetase T6 ins T
KCNMA1 potassium large conductance calcium-activated 
channel, subfam M, α1
T9 del T
PDS5A PDS5, regulator of cohesion maintenance, homolog A (S. cerevisiae) A6 del A
SFRS12IP1 SFRS12-interacting protein T10 ins T
TSHZ2 teashirt zinc finger homeobox 2 C7 del C
USP42 ubiquitin specific peptidase 42 A8 del A
Genes are ordered first by the frequency of mutation in MMR deficient prostate cancer samples and second alphabetically. 
The 3 MMR associated genes used as a positive control are depicted in red.
Figure 2: MNR repeat analysis of top mutated genes in prostate cancer in genomic DNA from prostate cancer cell 
lines PC346C (MMR deficient) and PC3 (MMR proficient). Fragment size analyses of PCR amplified fragments of CNOT1 A., 
DAB2IP B. and PRRT2 C. containing the repeat are presented. The highlighted peaks represent a mutant allele. PCR primers are presented 
in supplementary data. WT: wild type; del: deletion; ins: insertion. Indicated PRRT2 PCR fragments are flanked by sequence analysis of 
the repeat.
Oncotarget6047www.impactjournals.com/oncotarget
panels could be confirmed in primary cancer samples. 
We tested a total of 80 prostate cancer patient samples, 
including late stage and metastasised cancers. None 
of the samples displayed the mutations in either of the 
genes (data not shown), not unexpected because MSI 
is not frequent in clinical prostate cancer. Further, we 
tested 24 colorectal and 24 endometrial MSI patient 
cancer samples. We found PRRT2 to be mutated in 15 
out of 24 colorectal cancer patients and in 11 out of 
24 endometrial cancer patients (Supplementary Figure 
4, Supplementary Table 6). Although the mutation 
frequency in the DAB2IP MNR was similar (11/23), only 
one endometrium cancer sample displayed a mutation in 
the repeat. To further evaluate the significance of the 
mutation frequency of PRRT2 and DAB2IP in clinical 
MSI colorectal and endometrial cancer patient samples, 
we compared their frequency to the average mutation 
frequency for common MSI target genes published in 
databases (SelTarbase [31]) (Supplementary Table 7). 
Compared to other genes, PRRT2 displayed a very high 
mutation frequency in both colorectal and endometrial 
cancer and was selected for functional studies.
The PRRT2 gene
PRRT2 encodes a 340 amino acids protein that has 
two predicted transmembrane domains. This protein is 
poorly characterised, although recently a link between 
PRRT2 mutations and a rare neurological disease, 
paroxysmal kinesigenic dyskinesia, was established 
[32]. Whether PRRT2 has a role in cancer is unknown. 
Frameshifts in the C-repeat would result in expression 
of truncated proteins of 222 or 227 amino acids that lack 
the predicted transmembrane domains (Figure 3A). The 
PC346C prostate cancer cell line is the only cell line we 
identified, which has a mutation in both PRRT2 alleles. 
To investigate a possible role of PRRT2 in cancer we first 
documented PRRT2 expression levels by RNA sequencing 
in available cancer data sets (Supplementary Materials and 
Methods). Overall, PRRT2 showed a consistent decrease 
in expression in cancer as compared to normal in prostate, 
lung and gastric tissue samples (Figures 3B, 3C, 3D). Both 
lung and gastric cancers have been associated with MSI. 
In order to exclude non-mediated mRNA decay of the 
mutated PRRT2 transcript we investigated the expression 
Table 2: Number of MSI positive (MSI) and negative (MSS) prostate, colorectal, endometrial and ovarian cancer cell 
lines with mutations in the set of MSI target genes in PC346C
Prostate Cancer Colorectal Cancer Endometrial Cancer Ovarian Cancer
MSS MSI MSS MSI MSS MSI MSS MSI
CNOT1 0/3 4/4 0/3 9/10 0/3 4/4 0/2 1/3
DAB2IP 0/3 3/4 0/3 6/10 0/3 1/4 0/2 0/3
PRRT2 0/3 3/4 0/3 4/10 0/3 4/4 0/2 2/3
TTC3 0/3 2/4 0/3 5/10 0/3 1/4 0/2 0/3
CEP164 0/3 3/4 0/3 8/10 0/3 3/4 0/2 2/3
PHACTR4 0/3 3/4 0/3 7/10 0/3 3/4 0/2 1/3
TROVE2 0/3 1/4 0/3 5/10 0/3 4/4 0/2 1/3
ZFR 0/3 2/4 0/3 4/10 0/3 3/4 0/2 1/3
MLL3 0/3 2/4 0/3 8/10 0/3 3/4 0/2 1/3
ANLN 0/3 1/4 0/3 0/10 0/3 0/4 0/2 0/3
ANUBL1 0/3 1/4 0/3 2/10 0/3 0/4 0/2 0/3
EPRS 0/3 1/4 0/3 0/10 0/3 0/4 0/2 0/3
KCNMA1 0/3 1/4 0/3 6/10 0/3 1/4 0/2 1/3
PDS5A 0/3 1/4 0/3 0/10 0/3 1/4 0/2 0/3
SFRS12IP1 0/3 1/4 0/3 6/10 0/3 2/4 0/2 1/3
TSHZ2 0/3 1/4 0/3 10/10 0/3 3/4 0/2 3/3
USP42 0/3 1/4 0/3 4/10 0/3 4/4 0/2 0/3
The 3 control genes are depicted in red. Three MSS cell lines were available for prostate, colorectal and endometrial cancer 
and one MSS cell line for ovarian cancer. The number of MSI cell lines available for prostate, colorectal, endometrial and 
ovarian cancer were four, ten, four and three respectively.
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level of PRRT2 in PC346C. The elevated expression 
level detected suggested that the stability of the PRRT2 
transcript is not affected by the mutation (Supplementary 
Figure 5).
Biological activity of PRRT2
To assess whether the truncated PRRT2 (ΔPRRT2) 
influenced cell proliferation, we stable transfected the 
normal prostate epithelial cell line PNT2C2 with lentiviral 
constructs expressing wild type PRRT2 (PRRT2wt) or 
ΔPRRT2. Efficiency of transfection was assessed by the 
expression of GFP, independently transcribed under the 
CMV promoter. Cell proliferation was measured during 4 
days after plating of equal numbers of control (GFP only), 
PRRT2wt and ΔPRRT2 transfected cells.
A significant increase in proliferation capacity of 
PNT2C2 cells expressing ΔPRRT2 (37.5%) was observed 
as compared to the control cells at day 8. Conversely, the 
growth of PNT2C2 cells expressing PRRT2wt was impaired 
Figure 3: Expression pattern of PRRT2 mRNA. A. Schematic representation of the wildtype and the mutant PRRT2. The insertion 
of C and CC in the 9C repeat of PC346C leads to a truncated protein lacking the predicted transmembrane and cytoplasmatic domains. The 
frameshift occurs within the proline-rich region of PRRT2. B. Box plot analysis of PRRT2 mRNA in prostate cancer lymph node metastasis 
(LN-PCa, 12 samples), transurethral resections (TURP- PCa, 10 samples), primary prostate cancer (PCa, 56 samples) and normal adjacent 
prostate tissue (NAP, 12 samples). C. Expression levels of PRRT2 in lung adenocarcinoma (22 samples) and normal lung tissue (22 
samples). D. Expression levels of PRRT2 in gastric cancer (20 samples) and normal gastric tissue (20 samples). Wilcoxon testing was used 
in (B), (C) and (D) to determine significant differences in expression levels.
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especially as compared to the PNT2C2 cells expressing 
ΔPRRT2 (Figure 4A). The ΔPRRT2 effect on cellular 
proliferation was further validated in the RWPE-1 prostate 
epithelial cell line and the HCT116 colorectal cancer cell 
line. Both cell lines displayed the same growth promoting 
effect of ΔPRRT2. RWPE-1 cells stably expressing 
ΔPRRT2 showed an increase of 20% in proliferation 
capacity whereas PRRT2wt did not stimulate proliferation 
(Figure 4B). HCT116 cells expressing ΔPRRT2 showed an 
increase of 41% in proliferation capacity as compared to 
the control. Similar to PNT2C2, cells expressing PRRT2wt 
showed a decrease in cellular proliferation (Figure 4C). 
The cell cycle analysis of HCT116 and PNT2C2 cells 
revealed an increase in the percentage of cells in S-phase 
when ΔPRRT2 is present (Figure 4D and Supplementary 
Table 8).
The influence of PRRT2 expression on apoptosis 
was addressed in a caspase 3/7 activation assay in all 
ΔPRRT2 and PRRT2wt expressing cell lines described 
above. In none of the cases we observed a clear difference 
in apoptosis levels between ΔPRRT2, PRRT2wt and control 
GFP expressing cells (data not shown).
Finally we addressed the effect of PRRT2 on cell 
migration and invasion. PNT2C2, RWPE-1 and HCT116 
expressing ΔPRRT2, PRRT2wt and GFP were cultured 
in migration chambers for 24h in both presence and 
absence of 10% FCS. We detected a significant increase 
in migratory capacity of ΔPRRT2 expressing cells as 
compared to the GFP controls (Figure 5A and 5B). 
Migration of PRRT2wt expressing cells was consistently 
lower than the GFP control cells, but in all cases, not 
significantly different. In order to determine whether 
PRRT2 also promotes cell invasion we cultured PNT2C2 
and HCT116 cells expressing ΔPRRT2, PRRT2wt and 
GFP in collagen invasion chambers during 24h. Again, 
ΔPRRT2 expressing cells were more invasive compared 
to GFP and PRRT2wt expressing cells. (Figure 5C and 5D).
DISCUSSION
Microsatellite instability in cancer
The most prominent characteristic allowing 
cancer cells to survive, proliferate and disseminate is the 
Figure 4: PRRT2 affects cellular proliferation. A. PNT2C2, B. RWPE-1 and C. HCT116 cells were stably transduced with 
lentiviral vectors expressing the truncated form of PRRT2 (ΔPRRT2), the wildtype PRRT2 (wtPRRT2) and the control GFP vector. Cellular 
proliferation was measured 1, 2, 3 and 4 days after plating of the RWPE-1 and HCT116 cells, and 2, 4, 6 and 8 days after plating of the 
PNT2C2 cells. Cellular viability was measured by the reduction of luciferin into ocyluciferin in the presence of ATP. The y-axis displays the 
RLU (relative light units). Asterisks indicate *P≤0.02 and **P≤0.002, respectively, in a two-tailed Student’s t-test. D. The cell cycle profile 
of HCT116 and PNT2C2 cells expressing GFP, ΔPRRT2 and wtPRRT2 was determined measuring PI staining levels by flow cytometry.
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development of genomic instability [33]. DNA repair 
mechanisms are the cells’ surveillance systems and defects 
in this machinery are responsible for accelerating the rate 
at which cells can accumulate favourable genotypes. 
The MMR system eliminates base-base mismatches and 
insertion-deletion loops that arise during DNA replication 
due to slippage of the DNA polymerase [1]. Simple 
repetitive DNA sequences known as microsatellites 
are particularly prone to insertions and deletions due to 
defective MMR [34]. As a result, cells with a defective 
MMR system might have mutation rates 100-1000 fold 
higher than normal cells [35]. Several studies have shown 
that instability of microsatellites is present in PCa [36, 37]. 
The frequency of microsatellite instability detected in PCa 
is variable between different studies and ranges from 8% 
[38] to 35% [39, 40]. To elucidate the role of MMR in PCa 
we have sequenced the complete genome of the MMR-
deficient PC346C cell line. This cell line was derived from 
a transurethral resection of a primary tumor and lacks a 
functional MSH2 protein due to point mutations in both 
alleles [30].
The use of whole genome sequencing allowed 
an unbiased detection of all gene mutations and it is a 
powerful strategy to uncover genes implicated in the 
disease. Using this approach we identified a total of 
1196 gene mutations in PC346C. Approximately one 
third of these mutations occurred in nucleotide repeat 
sequences (see also ref [41]). The total number of gene 
mutations detected in G089 was 1.5 fold lower than in 
PC346C, which fits to the mutational phenotype due to 
MMR deficiency. Mutations in MNRs were enriched 
by 6-fold in PC346C as compared to G089. The bias in 
MNR mutations in PC346C as compared to G089 was 
used to select for gene mutations triggered by the MMR 
system. Several of the downstream target genes of MMR 
deficiency have shown to be key players in proliferation 
and apoptosis pathways.
Figure 5: PRRT2 plays a role in cellular migration and invasion. A. Migratory capacity of HCT116, PNT2C2 and RWPE-1 cells 
was assayed by measuring the cells migrating through a 5 μm polycarbonate membrane. Migration was induced by 10% FCS. Cells were 
assayed using CyQuant® GR fluorescent dye. All samples were normalized to the fluorescent detection in the absence of chemo attractant 
(10% FCS). RFU represents the relative fluorescent units. **P≤0.002 was calculated using a two-tailed Student’s t-test. B. Representative 
illustrations of migration of HCT116 cells expressing ΔPRRT2, wtPRRT2 or control GFP in the presence and absence of 10% FCS (see 
also legend to Figure 4). C. Cellular invasion of HCT116 and PNT2C2 cells was assayed using collagen-coated membranes. Invasion was 
induced by 10% FCS. Cells were assayed using the same method as for migration. D. Representative illustrations of invasion of HCT116 
cells expressing ΔPRRT2, wtPRRT2 or control GFP in the presence and absence of 10% FCS.
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Identification of novel MMR target genes in PCa
A list of 381 genes showing mutations in 
mononucleotide repeats in PC346C was used to select for 
novel target gene mutations caused by deficiency in the 
MMR system in PCa. Since the percentage of PCa cases 
with MSI was low we extended the test panel to include 
ovarian, endometrial and colorectal cancer cell lines. 
A final list of 13 candidate genes was further assessed 
for their mutation status in cell lines with and without 
microsatellite instability. We have first selected for the 
genes with the highest mutation frequencies in our prostate 
cancer cell line panel. Although TSHZ2 showed the highest 
mutation frequencies for colorectal and ovarian cancer cell 
lines only one out of the four MSI prostate cancer cell 
lines was positive for the TSHZ2 mutation. CNOT1 was 
mutated in all MSI prostate cancer cell lines but this was, 
in all cases, an heterozygous mutation and occurred closed 
to the end of the coding region. Both PRRT2 and DAB2IP 
were mutated in three out of the four MSI prostate cancer 
cell lines. Whereas PRRT2 mutations were also frequent 
in both colorectal, endometrial and ovarian cancer cell 
lines DAB2IP mutations were mostly restricted to prostate 
and colorectal cancer samples. DAB2IP has recently been 
identified as a regulator of tumour growth and apoptosis. 
The expression of DAB2IP is often downregulated in PCa 
and this downregulation causes activation of the RAS 
signalling cascade and inactivation of the ASK1-JNK 
pathway leading to growth stimulation and suppression 
of apoptosis [42, 43]. The observation that DAB2IP is 
mutated at high frequency in MMR deficient prostate and 
colorectal cell lines indicates a link between MMR and 
this gene. But so far, epigenetic suppression was suggested 
as the major mechanism behind DAB2IP downregulation 
[44]. Truncating mutations in PRRT2 were first identified 
in 2011 by Chen WJ et al. in paroxysmal kinesigenic 
dyskinesia (PKD) [32]. Although PRRT2 appears to be an 
important factor in several neurological-related conditions 
[45] there is no correlation between PRRT2 and other 
diseases. Also, there is little functional data regarding the 
PRRT2 protein with only one protein-protein interaction 
known so far with the synaptosomal-associated protein 25 
(SNAP25) [46].
PRRT2 and mismatch repair deficiency
The mutation status of PRRT2 and DAB2IP was 
assessed in a cohort of 24 colorectal and 24 endometrial 
MSI patient samples. We observed a high number of 
patients with mutations in PRRT2 and to a lesser extent 
mutations in DAB2IP were detected. The finding that 
DAB2IP was mutated in only one endometrial cancer 
sample indicates tissue specificity for this particular 
gene mutation. PRRT2 was frequently mutated in both 
colorectal and endometrial cancer patients. The frequency 
of PRRT2 mutation in patient samples is only second to the 
frequency of TGFβRII in colorectal cancer and the highest 
in endometrial cancer of all MSI genes (Supplementary 
Table 7) [47]. Although most targets of MMR deficiency 
are considered to be tumor suppressor genes that through 
the frameshift outcome lose their function there are 
also studies showing activating mutations such as the 
frameshifts in the TCF4 gene [48]. The two PRRT2 
frameshift mutations found in PC346C, the insertion of 
one or two Cs, occur in a C9 repeat in the second coding 
exon and introduce a premature stop codon in the mRNA. 
As a consequence, the PC346C cell line lacks a wild type 
PRRT2 protein. Although it is claimed that the non-sense 
mediated mRNA decay (NMR) mechanisms recognises 
premature stop codons and eliminate aberrant transcripts 
[49] we found a high level of expression of the PRRT2 
transcript in the PC346C cell line. The expression level of 
PRRT2 is overall lower in cancer as compared to normal, 
which would indicate it as a potential tumour suppressor 
gene. However mutations in this gene only affect one of 
the copies in almost all affected cancers, leaving a wild 
type PRRT2 copy intact. The PC346C prostate cancer 
cell line and patient from which the cell line is derived 
are the only samples with homozygous mutations in the 
9C repeat. Despite the lower expression of PRRT2 in 
cancer versus normal tissue our data suggests a dominant 
negative effect of the truncated PRRT2 protein
PRRT2 in proliferation and migration
To investigate the functional role of both the 
wild-type (PRRT2wt) and the truncated PRRT2 protein 
(ΔPRRT2) we generated stable PRRT2wt and ΔPRRT2 
expressing cell lines. Two normal prostate cell lines 
(PNT2C2 and RWPE-1) and one colorectal cancer cell 
line (HCT116) were used to assess the effect of PRRT2 
in proliferation, apoptosis and migration. Remarkably, 
we observed an oncogenic effect of ΔPRRT2. Both 
proliferation, migration and invasion were enhanced by 
stable ΔPRRT2 expression. Also, the cell cycle profile 
showed an enrichment of cells in S-phase and lesser cells 
in G1 suggesting these cells are cycling faster. Conversely, 
PRRT2wt appeared to decrease the proliferation rate, being 
this effect more evident in the PNT2C2 and HCT116 
cell lines as compared to RWPE-1. This decrease in 
proliferation by PRRT2wt overexpression suggests PRRT2 
to participate in cell cycle regulation. The frameshift 
mutation creates a truncated PRRT2 protein that 
increases both proliferation and migration in cell lines 
with a wild type PRRT2 protein. Based on our findings, 
we hypothesize that wild type PRRT2 inhibits slightly 
proliferation, whereas truncated PRRT2 can stimulate, and 
overrules wild type PRRT2. In this way it can function 
as an oncogene by promoting both proliferation and 
migration. Although genes are usually dichotomized in 
either oncogenes or tumor suppressors [50] many can 
actually exert both functions such as the Tp53 tumor 
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suppressor gene which can lead to tissue invasion, 
metastasis and increased proliferation when mutated [51].
In conclusion, a focused genome-wide sequencing 
approach, followed by subsequent expression and 
functional studies indicate mutated PRRT2 as a novel 
dominant oncogene, and wtPRRT2 as a candidate tumor 
suppressor gene. The finding that the same PRRT2 
mutation detected in this study has also been documented 
in colorectal, pancreatic and stomach cancer samples 
(depicted as A214P in Supplementary Figure 6) supports 
a more general role of PRRT2 in cancer biology.
MATERIALS AND METHODS
DNA samples used in whole genome and data 
analysis
The DNA of two prostate cancer samples, the 
PC346C prostate cancer cell line [52] and the G089 
prostate cancer patient, were sequenced by Complete 
Genomics (Complete Genomics Inc, CA). Tissue sample 
G089 and other patient materials described below has 
been collected according to national legislation concerning 
ethical requirements. Use of the clinical samples has been 
approved by the Erasmus MC Medical Ethics Committee 
according to the Medical Research Involving Human 
Subjects Act (MEC-2004-261). NCBI build 36 (hg18) 
was used as a reference genome during the mapping and 
data analysis process. Complete Genomics Inc. pipeline 
generated a report with all single nucleotide variants 
present in the two samples. Further information on the 
Complete Genomics Inc. data processing is present in 
supplementary materials and methods.
DNA from additional cell lines and tissue 
samples
Additional genomic DNA was isolated from MMR-
proficient prostate cancer cell lines PC3, PC135 and 
PC295 and MMR-deficient prostate cancer cell lines 
DU145, LNCaP and PC374. Cell pellets from thirteen 
colorectal, seven endometrial and three ovarian cancer 
cell lines were kindly provided by Dr. W. Dinjens, Dept 
Pathology, Erasmus MC, Rotterdam, The Netherlands.
Also, genomic DNA was isolated from frozen 31 
primary prostate cancer patient tissues, 37 transurethral 
resection of the prostate (TURP) samples and 11 lymph 
node prostate cancer metastasis samples. Genomic DNA 
from paraffin embedded formalin fixed tissue samples of 
24 microsatellite instable colorectal cancer patients and 
24 microsatellite instable endometrial cancer patients were 
kindly provided by Dr. W. Dinjens.
DNA isolation
DNA isolation from prostate cancer samples was 
performed using the QIAamp DNA Blood Midi Kit 
(Qiagen) according to the manufacturers’ instructions. Cell 
pellets were resuspended in 1 ml PBS (BioWhittaker) and 
instructions were followed according to the protocol used 
for 1 ml whole blood. DNA was eluted in 200 μl elution 
buffer.
DNA isolation from the colorectal, endometrial and 
ovarian cancer cell lines pellets was performed using the 
Gentra Puregene Cell Kit (Qiagen) (approx. 15 μg DNA 
from 2x106 cells) following the manufacturer’s protocol.
Concentration and purity of the DNA was assessed 
using the NanoDrop ND 1000 spectrophotometer 
(Nanodrop) by absorption measurements at 260 nm. DNA 
was stored at -20 degrees Celsius.
RNA isolation
Total RNA was isolated from PC346C, RWPE-
1, VCaP, HCT116 and PNT2C2 using the RNeasy kit 
(Qiagen) according to the manufacturer’s protocol. RNA 
was eluted in 50 μl RNase free water. Concentration 
and purity of RNA was assessed using the NanoDrop 
ND 1000 spectrophotometer (Nanodrop) by absorption 
measurements at 260 nm. RNA was stored at -80 degrees 
Celsius.
Cell culture
The PC346C cell line was cultured in DMEM-F12 
(BioWhittaker), supplemented with 2% (V/V) FCS (PAN 
Biotech), 1% insulintransferrin-selenium (GIBCO BRL), 
0.01% BSA (Boehringer-Mannheim), 10 ng/ml epidermal 
growth factor (Sigma-Aldrich) and 500 U penicillin-
streptomycin (BioWhittaker), 100 ng/ml bronectin (Harbor 
Bio Products), 20 mg/ml fetuine (ICN Biomedicals), 
0.1 nM R1881 (Sigma-Aldrich), 50 ng/ml cholera toxin 
(Sigma-Aldrich), 0.1 mM phosphoethanolamine (Sigma-
Aldrich), 0.6 ng/ml triodothyronine (Sigma-Aldrich), and 
500 ng/ml dexamethasone (Sigma-Aldrich). The PC346C 
cell line expresses the wild-type androgen receptor and 
secretes high levels of PSA. RWPE-1 cells were cultured 
in keratinocyte medium (GIBCO BRL), supplemented 
with 5 ng/ml epidermal growth factor, 1% penicillin-
streptomycin (BioWhittaker), and 50 mg/L bovine 
pituitary extract. RWPE-1 is a normal prostate epithelium 
cell line that is androgen-independent and expresses both 
the androgen receptor and PSA. The colorectal cancer cell 
line HCT116 and the normal prostate cell line PNT2C2 
cells were cultured in RPMI-1640 (GIBCO BRL), 
supplemented with 10% FCS (PAN Biotech) and 1% 
penicillin-streptomycin (BioWhittaker). All cell lines were 
cultured at 37 degrees in a 5% CO2 atmosphere.
Mononucleotide repeat analysis
A microsatellite instability assay was used to 
detect changes in the length of mononucleotide repeats 
by PCR amplification. Primers were designed using the 
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Primer3Plus program (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi). The final fragment 
size was set to vary between 100 and 130 bp in order to 
allow precise fragment sizing and robust amplification of 
all the genes tested. Primer sequences are described in 
Supplementary materials and methods. The M13 sequence 
(GTAAAACGACGGCCAGT) was added at the 5’ end 
of each forward primer. This enabled the use of a M13-
FAM primer to fluorescently label each PCR fragment. 
PCR reactions were performed in a total volume of 16 μl 
containing 12.5 ng genomic DNA, 3 μl 10x PCR Buffer 
(Quiagen), 2 μl 5x Q-Solution (Quiagen), 0.9 μl 25 mM 
MgCl2 (Quiagen), 0.3 μl dNTPs (10mM), 0.5 μl forward 
primer (100ng/μl), 0.5 μl M13-FAM primer (100ng/
μl), 1 μl reverse primer (100ng/μl), and 1 U HotStarTaq 
Polymerase (Quiagen). An initial denaturation step of 
15 min at 95 degrees Celsius was used to activate the 
HotstarTaq, followed by 35 cycles denaturation at 95 
degrees Celsius for 30 sec, an annealing step at 54 degrees 
Celsius for 30 sec and elongation at 72 degrees Celsius 
for 1 min. A final elongation step at 72 degrees Celsius 
for 10 min was used. PCR products were checked by 
electrophoresis in a 1% agarose gel.
Fragment analysis
The PCR products were separated by capillary 
electrophoresis using an ABI PRISM 3130 sequencing 
analyzer. This method allows single base pair resolution of 
PCR fragments. A mixture of 1.5 μl of the PCR products 
with 9.8 μl highly-deionized formamide (HiDi) and 0.2 
μl GeneScan-500 LIZ size standard (Applied Biosystems) 
was prepared. This mixture was heated for 2 min at 95 
degrees Celsius and subsequently loaded to the sequence 
analyzer. Data was analyzed with the Peak Scanner 
software (Applied Biosystems).
Sequencing
PCR products have been sequenced bi-directionally 
using standard Sanger sequencing. The sequencing 
reactions were carried out using the same forward and 
reverse primers as indicated above in the PCR but at 
different concentrations (3 ng primer per reaction). The 
final reaction volume was 20 μl. The sequencing products 
were precipitated using isopropanol and resuspended in 
20 ul formamide (Sigma-Aldrich). The PCR product was 
sequenced on an ABI Model 3730 automated sequencer 
and analyzed using DNAMAN (Lynnon Corporation).
PRRT2 expression constructs
The sequence validated I.M.A.G.E clone 
IRATp970E0579D corresponding to the BC053594 
clone accession number was purchased from Source 
Bioscience, Nottingham, UK. This plasmid contains the 
wtPRRT2 cDNA sequence. Primers 5’ GAT CGA ATT 
CGT TTG CCG CTG TCT CT 3’ (Fw) and 5’ GAT CGC 
GGC CGC TCA CTT ATA CAC GCC 3’ (Rv) were used 
to amplify the wtPRRT2 cDNA and subsequently clone 
the fragment into the pCDH-CMV-MCS-EF1-GFP-T2A-
Puro vector (System Biosciences). Primers 5’ GAT CGA 
ATT CGT TTG CCG CTG TCT CT 3’ (Fw) and 5’ GAT 
CGC GGC CGC CCC TTC TCA TTC GAT 3’ (Rv) were 
used to generate a truncated PRRT2 cDNA fragment. 
This fragment was integrated into the pCDH-CMV-MCS-
EF1-GFP-T2A-Puro vector (System Biosciences) for 
expression of ΔPRRT2 protein. The amplified fragments 
were ligated to the vector using the Rapid DNA Ligation 
Kit according to the manufacturer’s protocol (Roche). 
JM109 competent bacteria (Promega) were transformed 
with the ligation products using the heat shock method and 
plated in Ampicillin LB agar plates. DNA isolation was 
performed on selected colonies (Quiagen) and restriction 
enzyme reactions (BamHI and NotI ) confirmed the proper 
ligation of fragment to vector.
Lentivirus production
HEK293T cells were co-transfected with pCDH-
wtPRRT2-GFP-Puro or pCDH-ΔPRRT2-GFP-Puro or 
pCDH-GFP-Puro expression vectors and pPAX2 and 
pMD2.G (kind gift of Prof Didier Trono, Switserland) 
using the calcium phosphate precipitation method. 
Virus was harvested from the supernatant and used for 
transduction of PNT2C2, RWPE-1 and HCT116 cells. 
Pools of infected cells were propagated.
Functional role of PRRT2
The functional role of PRRT2 was assessed in 
RWPE-1, HCT116 and PNT2C2 cell lines expressing 
the truncated form of PRRT2 (ΔPRRT2), the wildtype 
PRRT2 (wtPRRT2) and the control GFP. These cell lines 
were propagated in medium supplemented with 1 μg/mL 
puromycin (Millipore). Briefly, cells were plated in 96-
well culture plates at a density of 1000 cells per well (100 
μl). Proliferation was assessed using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega), according 
to manufacturer’s protocol. Cell cycle analysis was 
performed by propidium iodide staining of the cell lines 
involved. Following cell pellet collection, fixation with 
70% ethanol was performed. Fixated cells were washed in 
PBS-0.05% Tween20 and ressuspended in 500 μL of PBS-
0.05% Tween20, RNases and PI. Samples were measured 
in FACS calibre following a 15 minute incubation with 
PI. Apoptosis was assessed using the ApoLive-Glo™ 
Multiplex Assay (Promega), which measures both the 
number of viable cells as a marker of cytotoxicity and 
caspase activation as a marker of apoptosis within a 
single assay well. The assay was performed according 
to the manufacturer’s protocol. As positive control of 
apoptosis an apoptosis inducer set (Millipore) was used. 
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A mix containing 700x dilutions of Actinomycin D (10 
mM), Camptothecin (2 mM), Cycloheximide (100 mM), 
Dexamethasone (10 mM) and Etoposide (10 mM) was 
supplemented for 24h to induce apoptosis. The QCM 
Chemotaxis Cell Migration Assay, 96-well (8 μm), 
fluorimetric (Millipore) was performed according to 
the manufacturer’s protocol. CytoSelect™ 24-Well Cell 
Invasion Assay, Collagen I was used to determine cell 
invasion according to the manufacturer’s protocol.
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